HOME PAGE  |  SET HOME  |  FAVORITE  |  简体中文  |  ENGLISH
 
Your present location:HOME PAGENews centerIndustry news > HKU has successfully developed H7N9 bird flu vaccine
Content

HKU has successfully developed H7N9 bird flu vaccine

Number of visits: Date:2014-07-24 23:03:36
According to Hong Kong, "Wen Wei Po" reported worldwide in recent years by various influenza viruses, including H7N9 and H5N1 avian flu. Faculty of Medicine and the National Institutes of Health in the smallpox vaccine, adding influenza virus genes, has successfully developed a new type of influenza vaccine against the avian flu virus H7N9 can and H5N1, seasonal influenza H3N2 and H1N1, and H7N7 highly pathogenic . Once large-scale outbreak of the flu, the vaccine can be mass-produced in a short time. In the rat experiments, the new vaccine to protect up to force 8 months 80-100%. Hong Kong University School of Public Health study published yesterday in the international academic journal published "American Academy of Sciences", and its research team in collaboration with researchers at the National Cancer Institute, National Institutes of Health, the success of the existing smallpox vaccine modified to "The new influenza vaccine. "New vaccine to mice experiments, and found mice resistant to a variety of influenza, including the current outbreak of H7N9 in mainland bird flu, H5N1 bird flu, human seasonal influenza H3N2 and H1N1, and highly pathogenic H7N7. Smallpox vaccine by mixing genes of influenza immunity The study launched since 2009, the new vaccine is based smallpox vaccine in the "attenuated vaccinia virus" as a carrier, and add five kinds of genes of H5N1 avian influenza virus, and injected to strengthen the immune response of human cytokines IL-15, so avian influenza virus into the vaccinia virus antigen protein. Research led by Associate Professor School of Public Health Panlie Wen said that in the past the development of influenza vaccines, are very dependent on whether it will produce antibodies to the virus. But the new vaccine can stimulate the identification of influenza A virus T lymphocytes, resulting in immunity, help to reduce the prevalence of the deadly disease and to shorten the time, and lead to better protection. Inoculation 7 days immune defense H5N1H7N9 Pan Liewen refers to experiments in mice, the mice inoculated with the new vaccine seven days will produce immunity. The researchers injected mice followed by high-dose influenza virus test, the result was the survival rate of mice were injected H5N1, H7N9, H3N2, H1N1 up to 100%; H7N7 virus is injected mice survival also 80%; without vaccination All mice in the control group mortality reached 100% of new vaccines. Panlie Wen said that since humans do not know what the future will be popular flu, while the existing seasonal influenza vaccine failed to prevent new bird flu, such as H5 and H7 avian influenza virus, it can enhance the urgent need to develop the various elements of the immune system, and cross-subtype virus protection effect of broad-acting influenza vaccine. "Attenuated vaccinia virus used in the manufacture of human smallpox vaccine, has been used more than one billion doses, therefore, when the vaccination requirements for an influenza pandemic and surge in new vaccine using the existing production equipment for large scale production." The next step test monkey marten Pan Liewen said the new vaccine is indeed much remains to be studied group can cope. The team will do next test in other animal models, including monkeys and marten, followed in order to carry out human clinical trials of new vaccines being available free period.
TypeInfo: Industry news Keywords for the information:
  TEL:86 379-65610020 FAX:86 379-63303179 Address:Mudan dadao 18#,Luolong area,Luoyang,Henan province
© 2014 Luoyang Huizhong Biotech Co.,Ltd. ALL RIGHTS RESERVED.
豫ICP备14012045号 TECHNICAL SURPPORT BY YICHANG.300.CN